vonoprazan
Jump to navigation
Jump to search
Indications
- in combination with amoxicillin & clarithromycin or with amoxicillin only for treatment of Helicobacter pylori infection (FDA approved May 2022)
- treatment of grade C/D esophagitis
* 10 day dual course (vonoprazan-amoxicillin) reportedly non-inferior to 14 day course of BMTL regimen[3]
Dosage
- esophagitis: start 20 mg PO QD, maintenance 10-20 mg PO QD
Adverse effects
- dysgeusia, diarrhea, abdominal pain, headache, nasopharyngitis, hypertension, vulvovaginal candidiasis
Mechanism of action
- K+ channel competitive blocker
Notes
More general terms
Component of
References
- ↑ Hamza Z Two New Regimens Win FDA Approval for H. Pylori Infection. Dual and triple vonoprazan-based treatments offer physicians another set of options. MedPage Today May 4, 2022 https://www.medpagetoday.com/gastroenterology/generalgastroenterology/98547
- ↑ Yan TL, Wang JH, He XJ, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial. Am J Gastroenterol. 2023 Dec 11 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37975609 https://journals.lww.com/ajg/fulltext/9900/ten_day_vonoprazan_amoxicillin_dual_therapy_vs.935.aspx
- ↑ 3.0 3.1 Yan TL, Wang JH, He XJ, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial. Am J Gastroenterol. 2023 Dec 11 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37975609 https://journals.lww.com/ajg/fulltext/9900/ten_day_vonoprazan_amoxicillin_dual_therapy_vs.935.aspx
- ↑ Zhuang Q, Chen S, Zhou X, et al. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis. Am J Gastroenterol. 2024 Mar 22. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38345252